Home
- Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P.
- Natrol Appoints Vincent Andrich VP Sales for Prolab Division
- Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results
- Body Shop Reports 24.8 Mil Euro Sales Revenues
- Supplement Group Targets Consumer Education
- Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing
- ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market
- Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products
- Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth
- Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities
- ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products
- Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace
- Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO
- drugstore.com Expects to Reach Profitability Target in 2003
- Human Genome Project Leads to Innovative Healthcare
- NPIcenter’s Career Center targets nutraceutical Industry
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Editorial: An Exercise in Synergy
- NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway
- Natural Health Trends Corp. Launches Lexxus Taiwan
- New TrimFit® Bars Redefine Energy Bar Category
- New TrimFit® Bars Redefine Energy Bar Category
- Probiata® Offers Safe, Natural and Effective Alternative
- Alive & Well with Michelle Harris
- Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com
- Consumers Search for Healthy Cleaning Products That Work
- Nordic Naturals: Omega 3 Fatty Acids
- Cyanotech Names Bob Capelli as Director of Sales
- Nutraceutical Clinical Laboratories International, Inc., Secures $2 Million in Funding
- KAVA ADVISORY: Health Canada is advising consumers not to use any products containing kava
- Defendants in International Spam Operation Settle FTC Charges; New Canadian Defendants Identified
Defendants in an operation that sold bogus weight loss supplements through illegal spam e-mail have settled Federal Trade Commission charges that their operation violated federal laws. The settlement bars them from making false or unsubstantiated claims about health benefits of any food, drug, or dietary supplements; bars violations of the Controlling the Assault of Non-Solicited Pornography and Marketing Act of 2003, known as the CAN-SPAM Act; and requires them to give up $29,000 in ill-gotten gains.
- Clarinol(TM) CLA: Now GRAS-Approved
Lipid Nutrition has announced that FDA has issued a ‘no objection letter’ to the GRAS petition for Clarinol(TM) CLA, confirming its 'GRAS' status.
- Clarinol(TM) CLA: Now GRAS-Approved
Lipid Nutrition has announced that FDA has issued a ‘no objection letter’ to the GRAS petition for Clarinol(TM) CLA, confirming its 'GRAS' status.
- Clarinol(TM) CLA: Now GRAS-Approved
Lipid Nutrition has announced that FDA has issued a ‘no objection letter’ to the GRAS petition for Clarinol(TM) CLA, confirming its 'GRAS' status.
- Clarinol(TM) CLA: Now GRAS-Approved
Lipid Nutrition has announced that FDA has issued a ‘no objection letter’ to the GRAS petition for Clarinol(TM) CLA, confirming its 'GRAS' status.
- Clarinol(TM) CLA: Now GRAS-Approved
Lipid Nutrition has announced that FDA has issued a ‘no objection letter’ to the GRAS petition for Clarinol(TM) CLA, confirming its 'GRAS' status.
- Federal Authorities Seize Xiadafil VIP Tablets After Company Refuses to Recall Product
At the request of the U.S. Food and Drug Administration, U.S. Marshals seized nearly $74,000 worth of Xiadafil VIP tablets, Lots 6K029 and 6K209-SEI, distributed by SEI Pharmaceuticals, Inc. of Miami, Fla. Although marketed as a dietary supplement to treat erectile dysfunction (ED) and for sexual enhancement, these lots represent an illegally marketed drug containing an undeclared ingredient.
- Federal Authorities Seize Xiadafil VIP Tablets After Company Refuses to Recall Product
At the request of the U.S. Food and Drug Administration, U.S. Marshals seized nearly $74,000 worth of Xiadafil VIP tablets, Lots 6K029 and 6K209-SEI, distributed by SEI Pharmaceuticals, Inc. of Miami, Fla. Although marketed as a dietary supplement to treat erectile dysfunction (ED) and for sexual enhancement, these lots represent an illegally marketed drug containing an undeclared ingredient.
- Federal Authorities Seize Xiadafil VIP Tablets After Company Refuses to Recall Product
At the request of the U.S. Food and Drug Administration, U.S. Marshals seized nearly $74,000 worth of Xiadafil VIP tablets, Lots 6K029 and 6K209-SEI, distributed by SEI Pharmaceuticals, Inc. of Miami, Fla. Although marketed as a dietary supplement to treat erectile dysfunction (ED) and for sexual enhancement, these lots represent an illegally marketed drug containing an undeclared ingredient.
- Federal Authorities Seize Xiadafil VIP Tablets After Company Refuses to Recall Product
At the request of the U.S. Food and Drug Administration, U.S. Marshals seized nearly $74,000 worth of Xiadafil VIP tablets, Lots 6K029 and 6K209-SEI, distributed by SEI Pharmaceuticals, Inc. of Miami, Fla. Although marketed as a dietary supplement to treat erectile dysfunction (ED) and for sexual enhancement, these lots represent an illegally marketed drug containing an undeclared ingredient.
- Cognis’ Tonalin® CLA Achieves FDA GRAS Status
Cognis Nutrition and Health has announced that the U.S. Food and Drug Administration (FDA) issued a ‘no questions letter’ to Cognis’ GRAS notification (GRN 00232).
- Cognis’ Tonalin® CLA Achieves FDA GRAS Status
Cognis Nutrition and Health has announced that the U.S. Food and Drug Administration (FDA) issued a ‘no questions letter’ to Cognis’ GRAS notification (GRN 00232).
- Cognis’ Tonalin® CLA Achieves FDA GRAS Status
Cognis Nutrition and Health has announced that the U.S. Food and Drug Administration (FDA) issued a ‘no questions letter’ to Cognis’ GRAS notification (GRN 00232).
- Cognis’ Tonalin® CLA Achieves FDA GRAS Status
Cognis Nutrition and Health has announced that the U.S. Food and Drug Administration (FDA) issued a ‘no questions letter’ to Cognis’ GRAS notification (GRN 00232).
- Cognis’ Tonalin® CLA Achieves FDA GRAS Status
Cognis Nutrition and Health has announced that the U.S. Food and Drug Administration (FDA) issued a ‘no questions letter’ to Cognis’ GRAS notification (GRN 00232).
- Cognis’ Tonalin® CLA Achieves FDA GRAS Status
Cognis Nutrition and Health has announced that the U.S. Food and Drug Administration (FDA) issued a ‘no questions letter’ to Cognis’ GRAS notification (GRN 00232).
- Cognis’ Tonalin® CLA Achieves FDA GRAS Status
Cognis Nutrition and Health has announced that the U.S. Food and Drug Administration (FDA) issued a ‘no questions letter’ to Cognis’ GRAS notification (GRN 00232).
- Cognis’ Tonalin® CLA Achieves FDA GRAS Status
Cognis Nutrition and Health has announced that the U.S. Food and Drug Administration (FDA) issued a ‘no questions letter’ to Cognis’ GRAS notification (GRN 00232).
- Novel food catalogue clarity reassuring but concerns remain says EHPM
European trade organisation EHPM has said it is ‘reassured’ by a statement from the European Commission that its recently published novel food catalogue is not legally binding for EU Member States, but has held concerns that listing an ingredient in the catalogue could prejudice its members’ products commercial viability because it may in practice be considered by some national authorities as a novel food ingredient.
- Novel food catalogue clarity reassuring but concerns remain says EHPM
European trade organisation EHPM has said it is ‘reassured’ by a statement from the European Commission that its recently published novel food catalogue is not legally binding for EU Member States, but has held concerns that listing an ingredient in the catalogue could prejudice its members’ products commercial viability because it may in practice be considered by some national authorities as a novel food ingredient.
- Novel food catalogue clarity reassuring but concerns remain says EHPM
European trade organisation EHPM has said it is ‘reassured’ by a statement from the European Commission that its recently published novel food catalogue is not legally binding for EU Member States, but has held concerns that listing an ingredient in the catalogue could prejudice its members’ products commercial viability because it may in practice be considered by some national authorities as a novel food ingredient.
- Novel food catalogue clarity reassuring but concerns remain says EHPM
European trade organisation EHPM has said it is ‘reassured’ by a statement from the European Commission that its recently published novel food catalogue is not legally binding for EU Member States, but has held concerns that listing an ingredient in the catalogue could prejudice its members’ products commercial viability because it may in practice be considered by some national authorities as a novel food ingredient.
- Novel food catalogue clarity reassuring but concerns remain says EHPM
European trade organisation EHPM has said it is ‘reassured’ by a statement from the European Commission that its recently published novel food catalogue is not legally binding for EU Member States, but has held concerns that listing an ingredient in the catalogue could prejudice its members’ products commercial viability because it may in practice be considered by some national authorities as a novel food ingredient.
- Novel food catalogue clarity reassuring but concerns remain says EHPM
European trade organisation EHPM has said it is ‘reassured’ by a statement from the European Commission that its recently published novel food catalogue is not legally binding for EU Member States, but has held concerns that listing an ingredient in the catalogue could prejudice its members’ products commercial viability because it may in practice be considered by some national authorities as a novel food ingredient.
- Capsugel Obtains Australia’s TGA Certification For Its Licaps® Liquid-Fill Capsule Manufacturing Facility
Capsugel has announced that it has received certification from the Therapeutic Goods Administration (TGA) for its Licaps® liquid-fill capsule production facility in Greenwood, S.C. (USA).
- Capsugel Obtains Australia’s TGA Certification For Its Licaps® Liquid-Fill Capsule Manufacturing Facility
Capsugel has announced that it has received certification from the Therapeutic Goods Administration (TGA) for its Licaps® liquid-fill capsule production facility in Greenwood, S.C. (USA).
- Capsugel Obtains Australia’s TGA Certification For Its Licaps® Liquid-Fill Capsule Manufacturing Facility
Capsugel has announced that it has received certification from the Therapeutic Goods Administration (TGA) for its Licaps® liquid-fill capsule production facility in Greenwood, S.C. (USA).
- Capsugel Obtains Australia’s TGA Certification For Its Licaps® Liquid-Fill Capsule Manufacturing Facility
Capsugel has announced that it has received certification from the Therapeutic Goods Administration (TGA) for its Licaps® liquid-fill capsule production facility in Greenwood, S.C. (USA).
- Capsugel Obtains Australia’s TGA Certification For Its Licaps® Liquid-Fill Capsule Manufacturing Facility
Capsugel has announced that it has received certification from the Therapeutic Goods Administration (TGA) for its Licaps® liquid-fill capsule production facility in Greenwood, S.C. (USA).
- EAS Gives Regulatory Crash Course
International food and nutrition policy consultancy EAS will be hosting a workshop entitled ‘Building a Regulatory Strategy for Marketing Food Supplements in Europe: The key steps to a successful product launch,’ October 9th, in Brussels.
- EAS Gives Regulatory Crash Course
International food and nutrition policy consultancy EAS will be hosting a workshop entitled ‘Building a Regulatory Strategy for Marketing Food Supplements in Europe: The key steps to a successful product launch,’ October 9th, in Brussels.
- EAS Gives Regulatory Crash Course
International food and nutrition policy consultancy EAS will be hosting a workshop entitled ‘Building a Regulatory Strategy for Marketing Food Supplements in Europe: The key steps to a successful product launch,’ October 9th, in Brussels.
- EAS Gives Regulatory Crash Course
International food and nutrition policy consultancy EAS will be hosting a workshop entitled ‘Building a Regulatory Strategy for Marketing Food Supplements in Europe: The key steps to a successful product launch,’ October 9th, in Brussels.
- EAS Gives Regulatory Crash Course
International food and nutrition policy consultancy EAS will be hosting a workshop entitled ‘Building a Regulatory Strategy for Marketing Food Supplements in Europe: The key steps to a successful product launch,’ October 9th, in Brussels.
- EAS Gives Regulatory Crash Course
International food and nutrition policy consultancy EAS will be hosting a workshop entitled ‘Building a Regulatory Strategy for Marketing Food Supplements in Europe: The key steps to a successful product launch,’ October 9th, in Brussels.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- Four "Hi-Tech Pharmaceuticals" Case Defendants Plead Guilty to Importing and Distributing "Knock-Off" Prescription Drugs
Four men based in Georgia, USA, have plead guilty to conspiring to import and distribute adulterated, mislabeled and unapproved new drugs, and to commit mail and wire fraud.
- Four "Hi-Tech Pharmaceuticals" Case Defendants Plead Guilty to Importing and Distributing "Knock-Off" Prescription Drugs
Four men based in Georgia, USA, have plead guilty to conspiring to import and distribute adulterated, mislabeled and unapproved new drugs, and to commit mail and wire fraud.
- EFSA Adopts First Opinions on Health Claims Made on Foods Relating to Disease Risk Reduction and Children's Health
EFSA’s Panel on dietetic products, nutrition and allergies (NDA) has adopted its first series of opinions on claims referring to the reduction of disease risk, and children's development and health. Scientists of the NDA Panel examined the scientific evidence for 8 claims, 5 of which related to children’s health and 3 to disease risk reduction.
- EFSA Adopts First Opinions on Health Claims Made on Foods Relating to Disease Risk Reduction and Children's Health
EFSA’s Panel on dietetic products, nutrition and allergies (NDA) has adopted its first series of opinions on claims referring to the reduction of disease risk, and children's development and health. Scientists of the NDA Panel examined the scientific evidence for 8 claims, 5 of which related to children’s health and 3 to disease risk reduction.
- EFSA Adopts First Opinions on Health Claims Made on Foods Relating to Disease Risk Reduction and Children's Health
EFSA’s Panel on dietetic products, nutrition and allergies (NDA) has adopted its first series of opinions on claims referring to the reduction of disease risk, and children's development and health. Scientists of the NDA Panel examined the scientific evidence for 8 claims, 5 of which related to children’s health and 3 to disease risk reduction.
- EFSA Adopts First Opinions on Health Claims Made on Foods Relating to Disease Risk Reduction and Children's Health
EFSA’s Panel on dietetic products, nutrition and allergies (NDA) has adopted its first series of opinions on claims referring to the reduction of disease risk, and children's development and health. Scientists of the NDA Panel examined the scientific evidence for 8 claims, 5 of which related to children’s health and 3 to disease risk reduction.
- EFSA Adopts First Opinions on Health Claims Made on Foods Relating to Disease Risk Reduction and Children's Health
EFSA’s Panel on dietetic products, nutrition and allergies (NDA) has adopted its first series of opinions on claims referring to the reduction of disease risk, and children's development and health. Scientists of the NDA Panel examined the scientific evidence for 8 claims, 5 of which related to children’s health and 3 to disease risk reduction.
- EFSA Adopts First Opinions on Health Claims Made on Foods Relating to Disease Risk Reduction and Children's Health
EFSA’s Panel on dietetic products, nutrition and allergies (NDA) has adopted its first series of opinions on claims referring to the reduction of disease risk, and children's development and health. Scientists of the NDA Panel examined the scientific evidence for 8 claims, 5 of which related to children’s health and 3 to disease risk reduction.
- EFSA Adopts First Opinions on Health Claims Made on Foods Relating to Disease Risk Reduction and Children's Health
EFSA’s Panel on dietetic products, nutrition and allergies (NDA) has adopted its first series of opinions on claims referring to the reduction of disease risk, and children's development and health. Scientists of the NDA Panel examined the scientific evidence for 8 claims, 5 of which related to children’s health and 3 to disease risk reduction.
- EU as a global exporter of regulation
Simon Pettman, Director of international food and nutrition policy consultancy EAS, said that EU efforts to harmonise regulations across its 27 member states has drawn interest across the globe, highlighting that in many areas including the food sector, Europe is fast becoming an exporter of regulation.
- EU as a global exporter of regulation
Simon Pettman, Director of international food and nutrition policy consultancy EAS, said that EU efforts to harmonise regulations across its 27 member states has drawn interest across the globe, highlighting that in many areas including the food sector, Europe is fast becoming an exporter of regulation.
- EU as a global exporter of regulation
Simon Pettman, Director of international food and nutrition policy consultancy EAS, said that EU efforts to harmonise regulations across its 27 member states has drawn interest across the globe, highlighting that in many areas including the food sector, Europe is fast becoming an exporter of regulation.
- EU as a global exporter of regulation
Simon Pettman, Director of international food and nutrition policy consultancy EAS, said that EU efforts to harmonise regulations across its 27 member states has drawn interest across the globe, highlighting that in many areas including the food sector, Europe is fast becoming an exporter of regulation.
- EU as a global exporter of regulation
Simon Pettman, Director of international food and nutrition policy consultancy EAS, said that EU efforts to harmonise regulations across its 27 member states has drawn interest across the globe, highlighting that in many areas including the food sector, Europe is fast becoming an exporter of regulation.
- EU as a global exporter of regulation
Simon Pettman, Director of international food and nutrition policy consultancy EAS, said that EU efforts to harmonise regulations across its 27 member states has drawn interest across the globe, highlighting that in many areas including the food sector, Europe is fast becoming an exporter of regulation.
- EU as a global exporter of regulation
Simon Pettman, Director of international food and nutrition policy consultancy EAS, said that EU efforts to harmonise regulations across its 27 member states has drawn interest across the globe, highlighting that in many areas including the food sector, Europe is fast becoming an exporter of regulation.
- Cognis Meets International Standard for Food Safety
The Cognis esterification plant at the Nutrition & Health Competence Center in Illertissen, Germany, has received the internationally renowned certificate of quality ISO 22000:2005 from the certification body DQS GmbH. The worldwide standard for food safety places rigorous demands on all process levels and along the whole chain of food production – from choosing raw materials and producing ingredients to manufacturing consumer products.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Another Reason to Choose Healthy Lifestyle Habits
- Another Reason to Choose Healthy Lifestyle Habits
|
Basing the criteria for substantiating health claims only on evidence from human intervention studies is not practical, the International Alliance of Dietary/Food Supplement Associations (IADSA) has said.
Commenting on the latest draft Codex Alimentarius recommendations for the scientific basis of health claims, IADSA said that while the clinical trial model is one source of scientific data, it is not practical when applied to the reduction of risk of disease in persons generally regarded as ‘healthy’.
The text, which is being revised by an electronic working group of which IADSA is a member, states that short-term human intervention studies in healthy subjects should be the prime source of evidence in claims substantiation. It also makes no reference to evidence based on traditional knowledge and history of use.
The previous draft was sent back to the drawing board last year following concerns over the structure of the document and the weight given to the different types of evidence required for scientific substantiation.
“It is scientific dogma to state that health claims should be based primarily on well designed human intervention studies,” said Professor David Richardson, Scientific Adviser to the UK Council for Responsible Nutrition (CRN) and IADSA. “Much of what is already known about human health cannot be validated using ‘gold standard’ clinical trials. These studies are, of course, important, but they provide only one source of information. All sources of scientific data have inherent limitations, hence the need to focus on the totality of the available data and weighing of the evidence.”
IADSA referred to the approach taken in the draft as “medicine-based, aimed at deciding whether a drug can prevent, cure or alleviate a disease or medical condition in the treatment of well-defined groups of people at high risk of disease or already with a disease”. However, IADSA argued that nutrition studies in healthy people require a large sample sizes, long-term follow up, high rates of compliance and the taking into account of other lifestyle factors.
Professor Richardson said: “The scientific evidence to support the diet and health relationships for dietary guidelines and health claims for fruits and vegetables, and for whole grain cereals, are based mainly on human observational studies, not clinical interventions.”
The text, which will go through an eight-step process to completion, will be presented at the next Codex Nutrition Committee meeting in November this year.
ENDS
IADSA is the voice of the worldwide dietary supplement manufacturing sector and an accredited international non-governmental organization (INGO) with a seat at the table of the main international regulatory bodies.
IADSA has more than doubled in size since its creation in 1998, representing more than 50 trade associations and over 20,000 companies.
For more information contact David Pineda Ereño, IADSA Manager, Regulatory Affairs, 50 Rue de l’Association, 1000 Brussels, Belgium, tel: +32 (0)2 209 1155, fax: +32 (0)2 223 3064, or email davidpineda@iadsa.be, visit www.iadsa.org. |